Side-by-side · Research reference
LL-37vsMatrixyl
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED15/35 cited
BAnimal-MechanisticHUMAN-REVIEWED9/39 cited
LL-37
Cathelicidin · Human AMP
Broad-spectrumAntimicrobial activity
Endogenous · Secreted at inflammation sites
Matrixyl
Cosmeceutical Pentapeptide · Topical Anti-Aging
Topical · Dermal · Twice Daily
01Mechanism of Action
Parameter
LL-37
Matrixyl
Primary target
Dermal fibroblastsPaccola 2025
Pathway
hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption
Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling
Downstream effect
Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026Zhang 2026
Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025
Feedback intact?
—
—
Origin
Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)
Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022
Antibody development
—
—
02Dosage Protocols
Parameter
LL-37
Matrixyl
Endogenous expression
Constitutive in neutrophils, epithelial tissues
Upregulated during infection and inflammation.Pinheiro 2026
—
Exogenous (experimental)
Dose varies by study; antimalarial ~10–50 μM in vitro
No FDA-approved exogenous formulation.
—
Plasma levels (malaria)
Elevated in infected patients and miceHe 2026
Exogenous administration reduced parasitemia in murine models.He 2026
—
Evidence basis
In vitro, animal models, human observational
—
Formulation concentration
—
0.5–5% in topical vehicle
Common cosmeceutical range; higher concentrations in clinical formulations.
Application frequency
—
Twice daily (AM/PM)
Standard cosmeceutical protocol.
Duration
—
8–12 weeks minimum for visible effect
Collagen synthesis requires sustained application.
Vehicle
—
Serum, cream, or emulsion base
Lipophilic carriers enhance penetration.
04Side Effects & Safety
Parameter
LL-37
Matrixyl
Cytotoxicity (high dose)
Membrane disruption in host cells at supraphysiological concentrations
—
Pro-inflammatory signaling
Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026
—
Theoretical cancer risk
Immunomodulatory roles in tumor microenvironment under investigation
—
Irritation
—
Mild erythema, pruritus in sensitive skin (rare)
Allergic reaction
—
Contact dermatitis (uncommon)
Systemic absorption
—
Negligible — topical application only
Absolute Contraindications
LL-37
—Matrixyl
- ·Known hypersensitivity to palmitoyl peptides
Relative Contraindications
LL-37
- ·Active autoimmune disease (theoretical immune dysregulation)
Matrixyl
- ·Active dermatitis or open wounds at application site
05Administration Protocol
Parameter
LL-37
Matrixyl
1. Natural secretion
LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.
Wash face with gentle cleanser. Pat dry.
2. Experimental formulations
Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.
Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.
3. Stability considerations
LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026
Twice daily — morning and evening. Apply before heavier creams or sunscreen.
4. Storage
—
Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.
06Stack Synergy
LL-37
— no documented stacks
Matrixyl
+ GHK-Cu
Multi-pathwayMatrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.
- Matrixyl
- 0.5–5% topical serum · AM/PM
- GHK-Cu
- 1–2% topical serum · same application
- Frequency
- Twice daily
- Primary benefit
- Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity